The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19)

被引:11
作者
Sheikhpour, Mojgan [1 ,2 ]
机构
[1] Pasteur Inst Iran, Dept Mycobacteriol & Pulm Res, Tehran, Iran
[2] Pasteur Inst Iran, Microbiol Res Ctr, Tehran, Iran
关键词
COVID-19; clinical trials; therapeutic drugs; immunomodulatory; fluoxetine; SPIKE PROTEIN; POTENTIAL THERAPY; GREEN TEA; SARS-COV; FLUOXETINE; 2019-NCOV; CELLS; INHIBITION; RECEPTORS; APOPTOSIS;
D O I
10.2147/TCRM.S262936
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The coronavirus 2019 (COVID-19) has been known as a pandemic disease by the World Health Organization (WHO) worldwide. The drugs currently used for treatment of COVID-19 are often selected and tested based on their effectiveness in other diseases such as influenza and AIDS and their major identified targets are viral protease, host cell produced protease, viral RNA polymerase, and the interaction site of viral protein with host cell receptors. Until now, there are no approved therapeutic drugs for definitive treatment of this dangerous disease. Methods: In this article, all of the documentary information, such as clinical trials, original research and reviews, government's database, and treatment guidelines, were reviewed critically and comprehensively. Moreover, it was attempted to present the most common and effective drugs and strategies, to suggest the possible treatment way of COVID19 by focusing on the body's defense mechanism against pathogens. Results: Antiviral drugs and immune-modulatory agents with the traditional medicines using the natural compound are usual accessible treatments. Accordingly, they have better beneficence due to the large existence studies, long time follow-ups, proximity to the natural system, and the normal physiological routine of the pathogen and host interactions. Besides, the serotonergic and dopaminergic pathways are considered as attractive targets to treat human immune, infectious, and cancerous diseases. Fluoxetine, as a host-targeted small molecule with immunomodulatory action, may be known as effective drug for treatment and prevention of COVID19 disease, in combination with antiviral drugs and natural compounds. Conclusion: Co-administration of fluoxetine in the treatment of COVID19 could be considered due to the possibility of its interaction with ACE2 receptors, immune-modulatory function, and a proper immune response at the right time. Fluoxetine plays a beneficial role in reducing stress due to fear of infecting by COVID19 or worsening the disease and psychological support for the affected patients.
引用
收藏
页码:933 / 946
页数:14
相关论文
共 93 条
  • [1] Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
    Agostini, Maria L.
    Andres, Erica L.
    Sims, Amy C.
    Graham, Rachel L.
    Sheahan, Timothy P.
    Lu, Xiaotao
    Smith, Everett Clinton
    Case, James Brett
    Feng, Joy Y.
    Jordan, Robert
    Ray, Adrian S.
    Cihlar, Tomas
    Siegel, Dustin
    Mackman, Richard L.
    Clarke, Michael O.
    Baric, Ralph S.
    Denison, Mark R.
    [J]. MBIO, 2018, 9 (02):
  • [2] Ahmad A, 2020, EUR REV MED PHARMACO, V24, P4030, DOI 10.26355/eurrev_202004_20873
  • [3] Covid-19 and thymoquinone: Connecting the dots
    Ahmad, Ajaz
    Rehman, Muneeb U.
    Ahmad, Parvaiz
    Alkharfy, Khalid M.
    [J]. PHYTOTHERAPY RESEARCH, 2020, 34 (11) : 2786 - 2789
  • [4] Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds
    Anh-Tien Ton
    Gentile, Francesco
    Hsing, Michael
    Ban, Fuqiang
    Cherkasov, Artem
    [J]. MOLECULAR INFORMATICS, 2020, 39 (08)
  • [5] [Anonymous], 2020, INT J ANTIMICROB AG
  • [6] [Anonymous], 2015, ARTERIOSCL THROM VAS, DOI [10.1038/s41586-022-05363-z, DOI 10.1038/s41586-020-2012-7]
  • [7] [Anonymous], REV PANAMERICANA SAL
  • [8] Arafah A, 2020, ARCH MED RES, DOI [10.1016/j.arcmed.2020.05.01311, DOI 10.1016/J.ARCMED.2020.05.01311]
  • [9] Atluri S, 2020, PAIN PHYSICIAN, V23, pE71
  • [10] The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds
    Baez-Santos, Yahira M.
    St John, Sarah E.
    Mesecar, Andrew D.
    [J]. ANTIVIRAL RESEARCH, 2015, 115 : 21 - 38